Abstract: A random transient power test signal generator based on three-dimensional memristive discrete map, which utilizes a three-dimensional parallel bi-memristor Logistic map module to generate two pseudo-random sequences, and based on the sequences, uses two waveform output modules to generate transient voltage and transient current signals respectively, thus the random transient power testing signal is obtained. The map can significantly improve the complexity of chaos and greatly extend its range of chaos. In addition, a performance evaluation shows the map has more robust hyperchaotic behavior in much larger chaos range. Moreover, the random sequences generated by the map module combines with DDS, which can generate a transient power signal with completely random period, starting phase and ending phase.

Abstract: The invention belongs to the technical field of biomedical testing, and particularly relates to a biomarker for diagnosis, treatment, and prognosis for hepatocellular carcinoma bone metastasis (HCC) and application thereof. The application of biomarker VAPA for preparing a reagent or a kit for diagnosis, treatment, and prognosis for HCC bone metastasis. The application of the reagent that detects VAPA expression levels in blood and tissues for preparing a reagent or kit for diagnosis, treatment, and prognosis for HCC bone metastasis. Compared with the diagnostic kits in the prior art that can only detect bone metastasis after it has occurred, the VAPA described in this invention offers a more specific and sensitive assay kit for the early prediction, diagnosis, disease progression assessment, treatment efficacy evaluation, drug guidance, and prognosis assessment of HCC bone metastasis. Additionally, the VAPA may also serve as a target for therapeutic interventions in bone metastasis.

Abstract: Provided are a beveled light-emitting lamp bead, a beveled light-emitting lamp bead holder, a manufacturing method therefor, and a display device. The beveled light-emitting lamp bead holder includes a holder body and a metal holder embedded in the holder body, where the holder body is divided by the metal holder into a cup shield located on a top side and a support structure located on a bottom side, a cup bottom in the cup shield is provided with a chip mounting surface parallel to a cup rim top surface, a bottom portion of the support structure is provided with a soldering plane, the soldering plane is electrically connected to the chip mounting surface through the metal holder, and an inclination angle is formed between the chip mounting surface and the soldering plane.

Abstract: The application relates to a battery pack case and a battery pack. The battery pack case includes: a bottom plate and a side plate connected with the bottom plate, the bottom plate and the side plate surround to form an accommodating portion configured to accommodate a unit cell; the bottom plate is provided with a plurality of first grooves and a plurality of second grooves opening toward the accommodating portion, the plurality of first grooves are spaced apart from each other, the plurality of second grooves are spaced apart from each other, and the first grooves and the second grooves are arranged to cross each other. The bottom plate of the battery pack itself has good rigidity, is not prone to warp deformation, and can prevent the overflow of structural glue from contaminating the wiring harness or electrical components.

Abstract: The present disclosure relates to a method and system for evaluating the macro resilience of offshore oil well control equipment. The method for evaluating the macro resilience of offshore oil well control equipment comprises six steps: determining the type and strength of external disaster; calculating the failure rate of components; calculating the recovery rate of the components; modeling the BN for a degradation process; modeling the BN for a maintenance process; and calculating the resilience of the offshore oil well control equipment. A system for evaluating the macro resilience of offshore oil well control equipment comprises an external disaster evaluation module, a component failure rate calculation subsystem, a reliability degradation process simulation module, a fault identification module, a component recovery rate calculation module, a reliability recovery process simulation module, a reliability change curve derivation unit and an resilience calculation unit.

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).

Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.